TISIDB

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00505 HMG (high mobility group) box
Function	Transcriptional activator that binds with high affinity to the T-cell enhancer motif 5'-AACAAAG-3' motif.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000077 DNA damage checkpoint GO:0000082 G1/S transition of mitotic cell cycle GO:0001501 skeletal system development GO:0001655 urogenital system development GO:0001678 cellular glucose homeostasis GO:0001822 kidney development GO:0001838 embryonic epithelial tube formation GO:0001841 neural tube formation GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0002244 hematopoietic progenitor cell differentiation GO:0002320 lymphoid progenitor cell differentiation GO:0002328 pro-B cell differentiation GO:0002521 leukocyte differentiation GO:0002790 peptide secretion GO:0002791 regulation of peptide secretion GO:0002793 positive regulation of peptide secretion GO:0003007 heart morphogenesis GO:0003170 heart valve development GO:0003171 atrioventricular valve development GO:0003174 mitral valve development GO:0003179 heart valve morphogenesis GO:0003181 atrioventricular valve morphogenesis GO:0003183 mitral valve morphogenesis GO:0003205 cardiac chamber development GO:0003206 cardiac chamber morphogenesis GO:0003207 cardiac chamber formation GO:0003208 cardiac ventricle morphogenesis GO:0003209 cardiac atrium morphogenesis GO:0003211 cardiac ventricle formation GO:0003215 cardiac right ventricle morphogenesis GO:0003230 cardiac atrium development GO:0003231 cardiac ventricle development GO:0003279 cardiac septum development GO:0003281 ventricular septum development GO:0003283 atrial septum development GO:0003284 septum primum development GO:0003289 atrial septum primum morphogenesis GO:0003357 noradrenergic neuron differentiation GO:0006417 regulation of translation GO:0006473 protein acetylation GO:0006474 N-terminal protein amino acid acetylation GO:0006611 protein export from nucleus GO:0006913 nucleocytoplasmic transport GO:0006977 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0007050 cell cycle arrest GO:0007093 mitotic cell cycle checkpoint GO:0007159 leukocyte cell-cell adhesion GO:0007346 regulation of mitotic cell cycle GO:0007507 heart development GO:0009306 protein secretion GO:0009743 response to carbohydrate GO:0009746 response to hexose GO:0009749 response to glucose GO:0009914 hormone transport GO:0010001 glial cell differentiation GO:0010608 posttranscriptional regulation of gene expression GO:0010817 regulation of hormone levels GO:0010948 negative regulation of cell cycle process GO:0014009 glial cell proliferation GO:0015833 peptide transport GO:0016055 Wnt signaling pathway GO:0016331 morphogenesis of embryonic epithelium GO:0018076 N-terminal peptidyl-lysine acetylation GO:0018205 peptidyl-lysine modification GO:0018394 peptidyl-lysine acetylation GO:0019827 stem cell population maintenance GO:0021510 spinal cord development GO:0021515 cell differentiation in spinal cord GO:0021517 ventral spinal cord development GO:0021522 spinal cord motor neuron differentiation GO:0021782 glial cell development GO:0021915 neural tube development GO:0021953 central nervous system neuron differentiation GO:0023061 signal release GO:0030072 peptide hormone secretion GO:0030073 insulin secretion GO:0030098 lymphocyte differentiation GO:0030111 regulation of Wnt signaling pathway GO:0030177 positive regulation of Wnt signaling pathway GO:0030217 T cell differentiation GO:0030330 DNA damage response, signal transduction by p53 class mediator GO:0031016 pancreas development GO:0031018 endocrine pancreas development GO:0031365 N-terminal protein amino acid modification GO:0031396 regulation of protein ubiquitination GO:0031397 negative regulation of protein ubiquitination GO:0031570 DNA integrity checkpoint GO:0031571 mitotic G1 DNA damage checkpoint GO:0031647 regulation of protein stability GO:0032024 positive regulation of insulin secretion GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0033157 regulation of intracellular protein transport GO:0033500 carbohydrate homeostasis GO:0034248 regulation of cellular amide metabolic process GO:0034250 positive regulation of cellular amide metabolic process GO:0034284 response to monosaccharide GO:0035019 somatic stem cell population maintenance GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035270 endocrine system development GO:0035904 aorta development GO:0035905 ascending aorta development GO:0035909 aorta morphogenesis GO:0035910 ascending aorta morphogenesis GO:0042063 gliogenesis GO:0042110 T cell activation GO:0042593 glucose homeostasis GO:0042769 DNA damage response, detection of DNA damage GO:0042770 signal transduction in response to DNA damage GO:0042886 amide transport GO:0043543 protein acylation GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044773 mitotic DNA damage checkpoint GO:0044774 mitotic DNA integrity checkpoint GO:0044783 G1 DNA damage checkpoint GO:0044819 mitotic G1/S transition checkpoint GO:0044843 cell cycle G1/S phase transition GO:0045727 positive regulation of translation GO:0045786 negative regulation of cell cycle GO:0045787 positive regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0046822 regulation of nucleocytoplasmic transport GO:0046823 negative regulation of nucleocytoplasmic transport GO:0046825 regulation of protein export from nucleus GO:0046826 negative regulation of protein export from nucleus GO:0046879 hormone secretion GO:0046883 regulation of hormone secretion GO:0046887 positive regulation of hormone secretion GO:0048483 autonomic nervous system development GO:0048485 sympathetic nervous system development GO:0048514 blood vessel morphogenesis GO:0048736 appendage development GO:0048844 artery morphogenesis GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050796 regulation of insulin secretion GO:0050821 protein stabilization GO:0051047 positive regulation of secretion GO:0051051 negative regulation of transport GO:0051168 nuclear export GO:0051169 nuclear transport GO:0051222 positive regulation of protein transport GO:0051224 negative regulation of protein transport GO:0060070 canonical Wnt signaling pathway GO:0060173 limb development GO:0060174 limb bud formation GO:0060411 cardiac septum morphogenesis GO:0060412 ventricular septum morphogenesis GO:0060413 atrial septum morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060563 neuroepithelial cell differentiation GO:0060828 regulation of canonical Wnt signaling pathway GO:0060840 artery development GO:0060993 kidney morphogenesis GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071156 regulation of cell cycle arrest GO:0071158 positive regulation of cell cycle arrest GO:0071322 cellular response to carbohydrate stimulus GO:0071326 cellular response to monosaccharide stimulus GO:0071331 cellular response to hexose stimulus GO:0071333 cellular response to glucose stimulus GO:0071593 lymphocyte aggregation GO:0072001 renal system development GO:0072175 epithelial tube formation GO:0072331 signal transduction by p53 class mediator GO:0072395 signal transduction involved in cell cycle checkpoint GO:0072401 signal transduction involved in DNA integrity checkpoint GO:0072413 signal transduction involved in mitotic cell cycle checkpoint GO:0072422 signal transduction involved in DNA damage checkpoint GO:0072431 signal transduction involved in mitotic G1 DNA damage checkpoint GO:0090068 positive regulation of cell cycle process GO:0090087 regulation of peptide transport GO:0090263 positive regulation of canonical Wnt signaling pathway GO:0090276 regulation of peptide hormone secretion GO:0090277 positive regulation of peptide hormone secretion GO:0090317 negative regulation of intracellular protein transport GO:0098727 maintenance of cell number GO:0198738 cell-cell signaling by wnt GO:1901983 regulation of protein acetylation GO:1901985 positive regulation of protein acetylation GO:1901987 regulation of cell cycle phase transition GO:1901988 negative regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1901991 negative regulation of mitotic cell cycle phase transition GO:1902400 intracellular signal transduction involved in G1 DNA damage checkpoint GO:1902402 signal transduction involved in mitotic DNA damage checkpoint GO:1902403 signal transduction involved in mitotic DNA integrity checkpoint GO:1902806 regulation of cell cycle G1/S phase transition GO:1902807 negative regulation of cell cycle G1/S phase transition GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903321 negative regulation of protein modification by small protein conjugation or removal GO:1903532 positive regulation of secretion by cell GO:1903828 negative regulation of cellular protein localization GO:1904950 negative regulation of establishment of protein localization GO:1904951 positive regulation of establishment of protein localization GO:2000045 regulation of G1/S transition of mitotic cell cycle GO:2000134 negative regulation of G1/S transition of mitotic cell cycle GO:2000756 regulation of peptidyl-lysine acetylation GO:2000758 positive regulation of peptidyl-lysine acetylation GO:2000759 regulation of N-terminal peptidyl-lysine acetylation GO:2000761 positive regulation of N-terminal peptidyl-lysine acetylation
Molecular Function	GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001104 RNA polymerase II transcription cofactor activity GO:0001105 RNA polymerase II transcription coactivator activity GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003713 transcription coactivator activity GO:0046982 protein heterodimerization activity GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component	GO:0005667 transcription factor complex GO:0044798 nuclear transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3769402: Deactivation of the beta-catenin transactivating complex R-HSA-162582: Signal Transduction R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SOX4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SOX4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -3.17; FDR: 0.00979	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SOX4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.708	0.125
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.616	0.785
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.792	0.682
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.04	0.915
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.241	0.919
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.392	0.9
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.011	0.982
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.097	0.96
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.14	0.946
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.171	0.907
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.867	0.668
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.044	0.719

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SOX4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SOX4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SOX4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SOX4
Name	SRY (sex determining region Y)-box 4
Aliases	EVI16; SRY-related HMG-box gene 4; ecotropic viral integration site 16; Transcription factor SOX-4
Chromosomal Location	6p22.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SOX4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SOX4